Get the Stockscreener App
26.71
1.07%
-0.29
Mineralys Therapeutics Inc stock is traded at $26.71, with a volume of 648.86K.
It is down -1.07% in the last 24 hours and up +3.63% over the past month.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
See More
Previous Close:
$27.00
Open:
$27.03
24h Volume:
648.86K
Relative Volume:
0.45
Market Cap:
$2.35B
Revenue:
-
Net Income/Loss:
$-151.78M
P/E Ratio:
-12.97
EPS:
-2.0595
Net Cash Flow:
$-136.42M
1W Performance:
-1.40%
1M Performance:
+3.63%
6M Performance:
-18.52%
1Y Performance:
+87.31%
1-Day Range:
$26.47
$27.98
1-Week Range:
$25.92
$27.98
52-Week Range:
$12.59
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Name
Mineralys Therapeutics Inc
Sector
Industry
Phone
(888) 378-6240
Address
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
26.71 | 2.35B | 0 | -151.78M | -136.42M | -2.0595 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | TD Cowen | Buy |
| Jun-11-25 | Initiated | Jefferies | Hold |
| Jul-10-24 | Initiated | H.C. Wainwright | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | BofA Securities | Buy |
| Mar-07-23 | Initiated | Credit Suisse | Outperform |
| Mar-07-23 | Initiated | Evercore ISI | Outperform |
| Mar-07-23 | Initiated | Guggenheim | Buy |
| Mar-07-23 | Initiated | Stifel | Buy |
| Mar-07-23 | Initiated | Wells Fargo | Overweight |
View All
Mineralys Therapeutics Inc Stock (MLYS) Latest News
MLYS|Mineralys Therapeutics Inc|Price:26.730|Chg%:-0.270 - TradingKey
Mineralys Therapeutics Inc (MLYS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mineralys Chief Commercial Officer Eric Warren disposes of $199,900 in common shares - Bitget
Form 4 Mineralys Therapeutics Inc For: 23 July By Investing.com - Investing.com Nigeria
Mineralys Therapeutics CCO Eric Warren sells $199k in shares - Investing.com
Mineralys (NASDAQ: MLYS) CCO sells 7,438 shares after option exercise - Stock Titan
Form 4 Mineralys Therapeutics Inc For: 21 July By Investing.com - Investing.com Australia
Mineralys Therapeutics (MLYS) affiliate plans 7,438-share stock sale after options exercise - Stock Titan
Mineralys Therapeutics CMO David Rodman disposes of $11,036 in shares - Investing.com
Mineralys Therapeutics, Inc. (MLYS): Analyst Consensus Points to a Promising 83% Upside Potential - DirectorsTalk Interviews
Mineralys CMO David Malcom Rodman disposes of 416 common shares worth $11,036.48 - Bitget
Responsive Playbooks and the MLYS Inflection - Stock Traders Daily
Form 144 Mineralys Therapeutics For: 17 July By Investing.com - Investing.com Nigeria
Mineralys Therapeutics (MLYS) insider schedules 416-share sale after option exercise - Stock Titan
Mineralys Executive Stock Sale Analysis - Intellectia AI
A Mineralys Insider Banked a $557,000 Options Gain Before a December FDA Date - The Motley Fool
What to Know About This Mineralys Insider Sale Before a December FDA Date - The Motley Fool
Mineralys Therapeutics (MLYS) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Mineralys Therapeutics (MLYS) Q3 2025 earnings summary - Quartr
Mineralys therapeutics CMO Rodman sells $556,671 in shares By Investing.com - Investing.com South Africa
Mineralys therapeutics CMO Rodman sells $556,671 in shares - Investing.com UK
Form 4 Mineralys Therapeutics Inc For: 15 July By Investing.com - Investing.com South Africa
Mineralys Therapeutics CEO Jon Congleton sells $291,441 in stock By Investing.com - Investing.com South Africa
Insider Sell: CEO Jon Congleton Sells 10,700 Shares of Mineralys Therapeutics Inc (MLYS) - GuruFocus
Mineralys Therapeutics (MLYS) CMO sells 20,407 shares and exercises options - Stock Titan
Mineralys Therapeutics (MLYS) CEO logs 10,700-share sale under Rule 10b5-1 plan - Stock Titan
Planned 6,349-share stock sale by Mineralys Therapeutics (NASDAQ: MLYS) - Stock Titan
Frontier tech research, news & data - MLQ.ai
Planned 14,058-share sale at Mineralys Therapeutics (NASDAQ: MLYS) - Stock Titan
Form 144 Mineralys Therapeutics For: 13 July By Investing.com - Investing.com Australia
Mineralys Therapeutics (MLYS) insider plans 10,700-share Rule 144 stock sale - Stock Titan
Mineralys Therapeutics (MLYS) insider details stock option exercise and sales - Stock Titan
Number of shareholders of Mineralys Therapeutics, Inc. – NASDAQ:MLYS - TradingView
Mineralys Therapeutics CMO Rodman sells $65,781 in stock By Investing.com - Investing.com India
Mineralys Therapeutics CMO Rodman sells $65,781 in stock - Investing.com India
Form 4 Mineralys Therapeutics Inc For: 10 July By Investing.com - Investing.com Canada
Mineralys Therapeutics (MLYS) CMO sells 2,171 shares after option exercise - Stock Titan
Mineralys Therapeutics (MLYS) Slips 2% as Stock Tests Key Support LevelsPrice Action Signals - dars.gov.et
Mineralys Therapeutics Inc Stock (MLYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mineralys Therapeutics Inc Stock (MLYS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Warren Eric | Chief Commercial Officer |
Jul 21 '26 |
Sale |
26.87 |
7,438 |
199,885 |
38,400 |
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):